According to the 2022 Clinical Practice Guidelines for NPC by the Chinese Society of Clinical Oncology (CSCO), immunotherapy has become one of the recommended treatment options for NPC, with programmed cell death-1 (PD-1)/ programmed cell death-Ligand 1 (PD-L1) antibody therapy being the most representative 4-6. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.